Affimed NV (AFMD)

[stockguard]

AFMD Affimed N.V. NKMax America to study AFM24, SNK01 combination
Affimed N.V. and NKMax America announced that they entered into a clinical collaboration agreement to investigate the combination of AFM24, a CD16A/EGFR-targeted ICE, with the autologous NK cell product SNK01. Pursuant to the collaboration, the companies plan to explore the combination in a first-in-human proof-of-concept trial in patients with EGFR-expressing tumors. The agreement follows a previous collaboration between the two companies in the preclinical setting to better understand the combined activity of their respective platforms. The results of the preclinical collaboration have shown substantive synergy between Affimed's ICE molecules and NKMax America's autolo gous and cryopreserved allogeneic natural killer cell products. Under the agreement, the companies will contribute their respective product candidates and resources towards submitting an Investigational New Drug application to the U.S. FDA and a subsequent clinical trial. The clinical trial will combine NKMax America's SNK01 with AFM24 in the autologous setting with the option to expand the clinical trial to the allogeneic setting. The cost of the clinical study will be shared by Affimed and NKMax America. The agreement also provides for the opportunity to pursue further clinical study combinations with additional product candidates from both parties.